Core Insights - NorthStrive Biosciences, a subsidiary of PMGC Holdings, has provided an update on the timeline for Phase III of its AI Development Program in collaboration with Yuva Biosciences, with results expected in Q2 2026 [1][3] Group 1: Company Updates - NorthStrive Biosciences initiated Phase III of its AI Development Program on December 17, 2025, which is anticipated to last approximately 6 to 9 weeks [1] - Yuva Biosciences has developed improved sixth-generation classifier models that enhance screening accuracy and sensitivity, which will be utilized in the Phase III study [2] - The extended timeline for Phase III results is expected to yield more robust and reliable outcomes to support further development efforts [3] Group 2: Company Background - Yuva Biosciences specializes in mitochondrial sciences and employs advanced AI to identify therapeutic candidates targeting aging-related pathways, with its proprietary platform MitoNova™ [4] - NorthStrive Biosciences focuses on developing aesthetic medicines, with its lead asset EL-22 aimed at addressing obesity while preserving muscle during weight loss treatments [5] - PMGC Holdings is a diversified holding company that manages a portfolio through strategic acquisitions and investments across various industries [6]

Core Viewpoint - NorthStrive Biosciences Inc. has initiated Phase III of its AI Development Program in collaboration with Yuva Biosciences, marking a significant advancement in developing therapies for obesity and related metabolic conditions [1][2]. Group 1: Phase III Development - Phase III aims to build on Phase II results, where YuvaBio utilized its MitoNova™ AI platform to identify small-molecule candidates that promote mitochondrial health and muscle preservation, particularly relevant for patients using GLP-1 receptor agonists [2][7]. - The Phase III program will generate biological data on AI-selected compounds, including cytotoxicity screening and ANT1 expression testing, and is expected to last approximately 6 to 9 weeks [2][7]. Group 2: Company Background - Yuva Biosciences, Inc. focuses on leveraging mitochondrial science and AI to develop therapeutic candidates targeting aging-related and metabolic pathways, utilizing its proprietary MitoNova™ platform [3]. - NorthStrive Biosciences Inc. specializes in developing aesthetic medicines, with its lead asset, EL-22, designed to address muscle preservation during weight loss treatments [4]. - PMGC Holdings Inc. is a diversified holding company managing a portfolio of subsidiaries, including NorthStrive Biosciences, and is committed to exploring growth opportunities across various sectors [5].

Core Insights - Northstrive Biosciences Inc. has completed Phase II of its AI Development Program in collaboration with Yuva Biosciences, focusing on small molecule candidates to promote mitochondrial health for combating obesity and cardiac diseases [1][6] Company Overview - Northstrive Biosciences Inc. is a biopharmaceutical company under PMGC Holdings Inc., specializing in the development of aesthetic medicines, with its lead asset EL-22 aimed at preserving muscle during weight loss treatments [3] - PMGC Holdings Inc. is a diversified holding company that manages a portfolio through strategic acquisitions and investments across various industries [4] Collaboration Details - YuvaBio completed Phase II by compiling a targeted collection of compounds from 12 curated libraries, focusing on obesity, cardiometabolic disorders, and lipid & glucose metabolism [2] - The MitoNova™ AI platform was utilized to screen compounds for their potential impact on muscle preservation and metabolic health, resulting in a shortlist of candidates for biological validation [2][6]

Core Insights - Northstrive Biosciences Inc. has initiated Phase II of its AI Development Program in collaboration with Yuva Biosciences, focusing on leveraging the MitoNova™ platform to identify small molecule candidates that enhance mitochondrial health in obesity and cardiac diseases [1][6] Company Overview - Northstrive Biosciences Inc. is a biopharmaceutical company under PMGC Holdings Inc., specializing in the development of innovative aesthetic medicines, with its lead asset EL-22 aimed at preserving muscle during weight loss treatments [3] - PMGC Holdings Inc. is a diversified holding company managing a portfolio through strategic acquisitions and investments across various sectors, including three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC [4] Collaboration Details - The collaboration with YuvaBio involves using the MitoNova™ AI platform to virtually screen a large library of drug-like small molecules, predicting which candidates are most likely to promote mitochondrial health [2][6] - YuvaBio will analyze the screening results to identify opportunities for biological validation and compile a list of synthetic compounds aimed at muscle preservation and metabolic health [2]

Core Insights - Northstrive Biosciences Inc. has completed a Phase I strategic research and literature synthesis for its first-in-class oral myostatin-engineered probiotic, EL-22, aimed at addressing muscle-wasting conditions [1][7] - The analysis, conducted with Yuva Biosciences, provided insights into EL-22's mechanism of action and its potential to meet critical needs in muscle-wasting conditions such as GLP-1-associated atrophy and age-related sarcopenia [1][7] Company Overview - Northstrive Biosciences Inc. is a biopharmaceutical company under PMGC Holdings Inc., focusing on developing innovative aesthetic medicines [4] - The lead asset, EL-22, utilizes a myostatin-engineered probiotic approach to help preserve muscle during weight loss treatments, particularly with GLP-1 receptor agonists [4] Product Highlights - EL-22 employs a myostatin-engineered probiotic strategy to combat obesity-related muscle loss during weight loss treatments, offering a patient-friendly oral delivery method [2][4] - The product is designed to induce an immune response against myostatin, a key regulator of muscle growth, using genetically engineered Lactobacillus casei [2] Research Findings - The report highlights significant effects of EL-22 in mdx mice, including improvements in antibody production, serum creatine kinase levels, body weight, motor function, and muscle histology [7] - EL-22's unique oral vaccine approach distinguishes it from traditional systemic antibody or gene therapy methods, aiming to stimulate both mucosal and systemic immunity against myostatin [7] Market Positioning - With the rise of GLP-1 receptor agonists in obesity and diabetes treatment, EL-22 is strategically positioned to address the associated muscle loss concerns [7] - Northstrive plans to initiate a Phase 2 proof-of-concept trial targeting GLP-1 users and engage in regulatory discussions to advance EL-22 towards an IND filing in the U.S. [7]